Compare LCNB & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | SLDB |
|---|---|---|
| Founded | 1877 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5M | 444.9M |
| IPO Year | N/A | 2018 |
| Metric | LCNB | SLDB |
|---|---|---|
| Price | $16.73 | $5.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.82 |
| AVG Volume (30 Days) | 26.2K | ★ 910.5K |
| Earning Date | 01-29-2026 | 11-03-2025 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 220.73 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $89,312,000.00 | N/A |
| Revenue This Year | $18.04 | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $9.87 | ★ N/A |
| Revenue Growth | ★ 19.58 | N/A |
| 52 Week Low | $13.34 | $2.41 |
| 52 Week High | $17.84 | $7.37 |
| Indicator | LCNB | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 51.15 |
| Support Level | $16.32 | $5.68 |
| Resistance Level | $17.59 | $6.08 |
| Average True Range (ATR) | 0.42 | 0.37 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 32.17 | 41.51 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.